Allena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
-- Successfully Completed Initial Public Offering, Raising
-- Presented Final Results from Phase 2 Trials of ALLN-177 in Secondary Hyperoxaluria at ASN Kidney Week 2017
-- Received Orphan Drug Designation from the
“Our third quarter and recent accomplishments represent significant progress across our business,” said
Third Quarter and Recent Business Highlights:
ALLN-177: ALLN-177, Allena’s lead product candidate, is a first-in-class, non-absorbed, orally-administered enzyme for the treatment of severe hyperoxaluria. Allena expects to initiate the first of two planned pivotal Phase 3 clinical trials for ALLN-177 in enteric hyperoxaluria in the first quarter of 2018 and to announce topline data in the second half of 2019. The Company also plans to initiate a Phase 2 clinical trial of ALLN-177 in adolescents and adults with primary hyperoxaluria or severe forms of secondary hyperoxaluria in the first quarter of 2018, with interim data expected in the second half of 2018.
November 2017, Allena presented final results from its Phase 2 clinical trials of ALLN-177 in patients with secondary hyperoxaluria at the American Society of Nephrology (ASN) Kidney Week2017 in New Orleans, LA. In patients with enteric hyperoxaluria, ALLN-177 substantially reduced urinary oxalate (UOx) excretion and was well-tolerated, with no drug-related serious or severe adverse events (SAEs) and no discontinuations of study drug due to SAE. Also at the ASN meeting, Allena presented preclinical data from a porcine dietary model of severe hyperoxaluria, which showed a significant reduction in both plasma oxalate and UOx excretion. This preclinical study supported the Company’s orphan drug designation in primary hyperoxaluria and demonstrated animal proof-of-concept for the upcoming Phase 2 clinical trial in patients with severe hyperoxaluria and hyperoxalemia (elevated plasma oxalate). Hyperoxalemia increases the risk of systemic oxalosis, which refers to the presence of excess oxalate throughout the body, including the blood, bones, joints, eyes and heart.
July 2017, Allena received orphan drug designation from both the FDAand the European Commission for ALLN-177for the treatment of primary hyperoxaluria (PH). PH is a severe rare genetic disorder caused by endogenous overproduction of oxalate by the liver that can result in kidney stone disease, kidney damage, kidney failure, and systemic oxalosis, which may lead to death.
ALLN-346: ALLN-346, Allena’s second product candidate, is a first-in-class, orally-administered, non-absorbed, urate-degrading enzyme in preclinical development for patients with hyperuricemia and moderate to severe chronic kidney disease (CKD). These patients are challenging to manage due to limitations of existing therapies, such as poor tolerability, reduced efficacy, dose restriction or contraindications.
- Allena initiated a preclinical study for ALLN-346 in
December 2017and expects to file an investigational new drug (IND) application for ALLN-346 in the first half of 2019.
November 2017, Allena completed its initial public offering of common stock at $14.00per share, raising gross proceeds of $74.9 million.
Third Quarter 2017 Financial Results:
- Cash Position: As of
September 30, 2017, cash and cash equivalents were $33.9 million, as compared to cash, cash equivalents and short-term investments of $48.8 millionas of December 31, 2016. Cash and cash equivalents as of September 30, 2017do not include the proceeds from the Company’s initial public offering of common stock, which was completed in November 2017. The Company expects that its cash, cash equivalents, and short-term investments will enable it to fund its operating plan into 2020.
- R&D Expenses: R&D expenses were
$2.9 millionfor the third quarter of 2017, as compared to $5.3 millionfor the third quarter of 2016. This decrease was primarily due to the decrease in clinical costs. During the third quarter of 2016, the Company incurred clinical trial costs for its 649 and 713 studies for ALLN-177, which were active during the third quarter of 2016 and concluded prior to the third quarter of 2017.
- G&A Expenses: G&A expenses were
$1.4 millionfor the third quarter of 2017, as compared to $0.8 millionfor the third quarter of 2016. This increase was primarily due to an increase in legal and consulting costs incurred during the third quarter of 2017.
- Net Loss: Net loss was
$4.7 millionfor the third quarter of 2017, or $3.49per basic and diluted share, as compared to a net loss of $6.1 millionfor the third quarter of 2016, or $4.59per basic and diluted share.
Forward Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the safety, efficacy and potential clinical benefits of Allena’s product candidates, the timing of initiation of Allena’s planned Phase 3 clinical trials for ALLN-177 and the announcement of data from these trials, the timing of the filing of an IND for ALLN-346, and Allena’s financial condition and cash runway into 2020. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that results of earlier studies may not be predictive of future clinical trial results, and planned studies may not establish an adequate safety or efficacy profile for ALLN-177 and other product candidates that support regulatory approval; risks associated with the fact that Allena has not yet finalized the design of its pivotal Phase 3 clinical program for ALLN-177, including the primary and secondary endpoints and the statistical analyses for these planned Phase 3 clinical trials, and that the
Selected Condensed Consolidated Balance Sheet Data Sheet
|September 30, 2017||December 31, 2016|
|Cash, cash equivalents and short term investments||$||33,874||$||48,755|
|Working capital (1)||27,313||46,025|
|Loan payable, net of current portion and discount||6,620||9,409|
|Convertible preferred stock||95,779||95,727|
|Total stockholders' deficit||(74,000||)||(59,277||)|
(1) The Company defines working capital as current assets less current liabilities. See the Company’s condensed consolidated financial statements for further detail regarding its current assets and current liabilities.
Selected Condensed Consolidated Statement of Operations
(in thousands, except share and per share data)
|Three months ended September 30,||Nine months ended September 30,|
|Research and development||$||2,949||$||5,263||$||10,758||$||15,288|
|General and administrative||1,413||839||3,621||2,896|
|Total operating expenses||4,362||6,102||14,379||18,184|
|Other income (expense), net||(308||)||(34||)||(594||)||(104||)|
|Net loss per share attributable to common stockholders—basic and diluted||$||(3.49||)||$||(4.59||)||$||(11.19||)||$||(13.70||)|
|Weighted-average common shares outstanding—basic and diluted||1,343,429||1,341,385||1,342,898||1,338,539|
Stern Investor Relations, Inc.
Source: Allena Pharmaceuticals, Inc.